SITC Press Releases

Oncology News Burst from the FDA: FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic Hepatocellular Carcinoma

By SITC Communications posted 9 days ago
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Nivolumab With Ipilimumab for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer

By SITC Communications posted 14 days ago
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Durvalumab for Muscle Invasive Bladder Cancer

By SITC Communications posted 22 days ago
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

SITC Thanks FDA Leaders for Their Service

By Keegan Mager posted 23 days ago
Dear SITC Members, The Society for Immunotherapy of Cancer (SITC) would like to thank Peter Marks, MD, PhD, Marc Theoret, MD, and Paul Kluetz, MD, of the U.S. Food and Drug Administration (FDA) for their significant contributions across the field of oncology and their positive impact on public health. The development of cancer immunotherapy as we know it today - serving as first-line treatment for numerous cancer types - represents one such advance in oncology that would not have been possible without the tireless work ethic, collaboration, and determination of these individuals to improve ...
0 comments

Oncology News Burst from the FDA: FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection

By SITC Communications posted 01-02-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

The Arthur and Sandra Irving Cancer Symposium: Connect with Senior Cancer Immunology Faculty and Learn from Their Experience in Research

By SITC Communications posted 12-17-2024
From June 22-25, 2025, the Arthur and Sandra Irving Cancer Immunology Symposium in Boston will connect promising young researchers with leaders in the field. Participants gain insights through interactive sessions and one -on-one mentoring to support the next stage of scientific and professional development. Young scientists face numerous challenges navigating the cancer immunology landscape. With the support of the Arthur and Sandra Irving Foundation, we aim to provide early-career researchers with the mentorship and tools they need to advance scientific discovery and make ...
0 comments

Oncology News Burst from the FDA: FDA Approves Cosibelimab-ipdl for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

By SITC Communications posted 12-16-2024
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer

By SITC Communications posted 12-06-2024
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Obecabtagene Autoleucel for Adults with Relapsed or Refractory B-cell Precursor Acute lymphoblastic leukemia

By SITC Communications posted 11-11-2024
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

The Society for Immunotherapy of Cancer Announces Late-Breaking Abstracts and Press Briefing Presented at 39th Annual Meeting

By Thomas Martin posted 11-01-2024
The Society for Immunotherapy of Cancer Announces Late-Breaking Abstracts and Press Briefing Presented at 39 th Annual Meeting The Society for Immunotherapy of Cancer (SITC) received over 1,500 abstract submissions in 2024, and has announced titles and authors for 42 accepted Late-Breaking Abstracts (LBA). New for 2024, all of the Late-breaking Abstracts contain late-breaking data from interventional clinical trials in humans. The abstracts will be presented at SITC’s upcoming 39 th Annual Meeting & Pre-Conference Programs taking place November 6–10, 2024, in Houston, ...
0 comments

Clinical Late-Breaking Abstracts Announced for the Society for Immunotherapy of Cancer’s 39th Annual Meeting

By Thomas Martin posted 10-31-2024
Clinical Late-Breaking Abstracts Announced for the Society for Immunotherapy of Cancer’s 39 th Annual Meeting MILWAUKEE – The Society for Immunotherapy of Cancer (SITC) received an incredible number of abstract submissions in 2024, more than 1,500, including a record-breaking number of clinical based Late-breaking Abstracts. SITC is proud to announce the titles and authors for the clinical Late-breaking Abstracts (LBA) . The abstracts will be presented at SITC’s upcoming 39 th Annual Meeting & Pre-Conference Programs taking place November 6–10, 2024, in Houston, ...
0 comments

Oncology News Burst from the FDA: FDA Approves Neoadjuvant/Adjuvant Nivolumab for Resectable Non-Small Cell Lung Cancer

By SITC Communications posted 10-07-2024
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Pembrolizumab with Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

By SITC Communications posted 09-19-2024
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Atezolizumab and Hyaluronidase-tqjs for Subcutaneous Injection

By SITC Communications posted 09-16-2024
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Society for Immunotherapy of Cancer Forward Fund Announces Recipients of Cancer Immunotherapy Fellowships

By SITC Communications posted 08-19-2024
In its mission to make “cure” a reality for cancer patients everywhere and support the development of early career investigators, the Society for Immunotherapy of Cancer (SITC) Forward Fund is pleased to announce the recipients of its 2024 fellowships totaling $640,000. “With the generous support of our industry partners, SITC is able to back the promising research of early career investigators and future leaders in cancer immunotherapy,” said SITC President Leisha A. Emens, MD, PhD. “This investment in our field's future aims to develop new immunotherapy strategies and improve patient outcomes.” ...
0 comments